Voyager Therapeutics (NASDAQ:VYGR) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report published on Tuesday,RTT News reports. Wedbush currently has a $9.00 price target on the stock, down from their previous price target of $11.00. Wedbush also issued estimates for Voyager Therapeutics’ FY2029 earnings at ($0.86) EPS.

Other equities analysts have also issued research reports about the stock. Leerink Partners started coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective on the stock. Finally, StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Trading Down 0.9 %

NASDAQ:VYGR opened at $4.38 on Tuesday. The firm has a market capitalization of $239.28 million, a price-to-earnings ratio of 6.17 and a beta of 0.91. The firm’s fifty day simple moving average is $5.65 and its 200 day simple moving average is $6.32. Voyager Therapeutics has a twelve month low of $4.00 and a twelve month high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the business posted ($0.59) EPS. On average, analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 10,778 shares of company stock valued at $58,548 in the last quarter. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Voyager Therapeutics by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock worth $747,000 after purchasing an additional 5,365 shares during the period. Hunter Perkins Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Voyager Therapeutics by 7.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company’s stock worth $801,000 after purchasing an additional 9,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the period. Finally, Empowered Funds LLC boosted its holdings in shares of Voyager Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.